Professor Jonathan Heeney

Cambridge vaccine expert in $42million partnership to develop 'future-proofed' coronavirus vaccines

08 March 2022

Prime Minister Boris Johnson announced that DIOSynVax, a biotech spinout of the University of Cambridge, will receive $42 million (about £32 million) to develop a vaccine candidate that could provide protection against both existing and future variants of SARS-CoV-2 – the virus that causes COVID-19 – as well as other major coronaviruses, including those that cause SARS and MERS.

Read More
SemaCyte cell assaying platform

Drug-screening spin-out secures new funding

23 February 2022

A University of Cambridge spin-out company from the Cavendish Laboratory, combines materials engineering and cell biology to help biopharma companies make better medicines, faster. It announced today that it has closed a £2.14 million seed funding round.

Read More
Xavier Moya

Zero-carbon refrigeration spin-out sets its sights on environmentally-friendly heating systems

16 February 2022

Zero-carbon refrigeration pioneer Barocal has secured a £1.3 million investment to accelerate commercialisation of its novel technology designed to cut global CO₂ emissions. As the technology also works in heating applications, the University of Cambridge spin-out now plans to explore the potential of its breakthrough for domestic and commercial heating systems—to provide a cost-effective, efficient alternative to expensive air source heat pumps.

Read More

Cambridge COVID vaccine in clinical trials

14 December 2021

Safety trials are underway for a vaccine developed by Cambridge researchers that could be used as a booster targeting COVID-19 virus variants and relatives that threaten future coronavirus pandemics.

Read More

Pages